Connection

ALEXANDER LAZAR to Animals

This is a "connection" page, showing publications ALEXANDER LAZAR has written about Animals.
Connection Strength

0.451
  1. RNA interference of PARG could inhibit the metastatic potency of colon carcinoma cells via PI3-kinase/Akt pathway. Cell Physiol Biochem. 2012; 29(3-4):361-72.
    View in: PubMed
    Score: 0.018
  2. The molecular pathology of sarcomas. Cancer Biomark. 2010; 9(1-6):475-91.
    View in: PubMed
    Score: 0.015
  3. An iron-rich subset of macrophages promotes tumor growth through a Bach1-Ednrb axis. J Exp Med. 2024 Oct 07; 221(10).
    View in: PubMed
    Score: 0.010
  4. Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types. Clin Cancer Res. 2024 May 15; 30(10):2121-2139.
    View in: PubMed
    Score: 0.010
  5. ASPSCR1-TFE3 reprograms transcription by organizing enhancer loops around hexameric VCP/p97. Nat Commun. 2024 Feb 07; 15(1):1165.
    View in: PubMed
    Score: 0.010
  6. Cell membrane-anchored and tumor-targeted IL-12 T-cell therapy destroys cancer-associated fibroblasts and disrupts extracellular matrix in heterogenous osteosarcoma xenograft models. J Immunother Cancer. 2024 01 09; 12(1).
    View in: PubMed
    Score: 0.010
  7. Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma. Cancer Immunol Res. 2023 05 03; 11(5):558-569.
    View in: PubMed
    Score: 0.009
  8. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022 06; 606(7915):797-803.
    View in: PubMed
    Score: 0.009
  9. The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma. Nat Commun. 2022 06 01; 13(1):3057.
    View in: PubMed
    Score: 0.009
  10. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022 05 09; 40(5):509-523.e6.
    View in: PubMed
    Score: 0.009
  11. The FUS::DDIT3 fusion oncoprotein inhibits BAF complex targeting and activity in myxoid liposarcoma. Mol Cell. 2022 05 05; 82(9):1737-1750.e8.
    View in: PubMed
    Score: 0.009
  12. Experimental models of undifferentiated pleomorphic sarcoma and malignant peripheral nerve sheath tumor. Lab Invest. 2022 06; 102(6):658-666.
    View in: PubMed
    Score: 0.009
  13. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021 Dec 24; 374(6575):1632-1640.
    View in: PubMed
    Score: 0.009
  14. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma. Oncoimmunology. 2021; 10(1):1992880.
    View in: PubMed
    Score: 0.009
  15. The clear cell sarcoma functional genomic landscape. J Clin Invest. 2021 08 02; 131(15).
    View in: PubMed
    Score: 0.008
  16. Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state. Acta Neuropathol. 2021 09; 142(3):565-590.
    View in: PubMed
    Score: 0.008
  17. Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy. Cell Rep. 2021 07 20; 36(3):109410.
    View in: PubMed
    Score: 0.008
  18. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021 08; 27(8):1432-1441.
    View in: PubMed
    Score: 0.008
  19. Combined VEGFR and MAPK pathway inhibition in angiosarcoma. Sci Rep. 2021 04 30; 11(1):9362.
    View in: PubMed
    Score: 0.008
  20. Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma. Cell Rep. 2020 10 20; 33(3):108293.
    View in: PubMed
    Score: 0.008
  21. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discov. 2019 05; 9(5):628-645.
    View in: PubMed
    Score: 0.007
  22. p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell. 2019 02 11; 35(2):204-220.e9.
    View in: PubMed
    Score: 0.007
  23. T-cell trafficking plays an essential role in tumor immunity. Lab Invest. 2019 01; 99(1):85-92.
    View in: PubMed
    Score: 0.007
  24. A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov. 2018 05; 8(5):556-567.
    View in: PubMed
    Score: 0.007
  25. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018 01 05; 359(6371):97-103.
    View in: PubMed
    Score: 0.006
  26. Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma. Cancer Biol Ther. 2017 10 03; 18(10):816-826.
    View in: PubMed
    Score: 0.006
  27. NF1+/- Hematopoietic Cells Accelerate Malignant Peripheral Nerve Sheath Tumor Development without Altering Chemotherapy Response. Cancer Res. 2017 08 15; 77(16):4486-4497.
    View in: PubMed
    Score: 0.006
  28. PRKCI promotes immune suppression in ovarian cancer. Genes Dev. 2017 06 01; 31(11):1109-1121.
    View in: PubMed
    Score: 0.006
  29. Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis. Oncogene. 2017 09 21; 36(38):5421-5431.
    View in: PubMed
    Score: 0.006
  30. Modeling synovial sarcoma metastasis in the mouse: PI3'-lipid signaling and inflammation. J Exp Med. 2016 12 12; 213(13):2989-3005.
    View in: PubMed
    Score: 0.006
  31. IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. J Natl Cancer Inst. 2016 12; 108(12).
    View in: PubMed
    Score: 0.006
  32. Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation. Lab Invest. 2016 08; 96(8):885-94.
    View in: PubMed
    Score: 0.006
  33. Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor. Cancer Biol Ther. 2016; 17(2):129-38.
    View in: PubMed
    Score: 0.006
  34. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16.
    View in: PubMed
    Score: 0.006
  35. Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas. BMC Cancer. 2015 Nov 10; 15:886.
    View in: PubMed
    Score: 0.006
  36. SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma. Clin Cancer Res. 2016 Mar 01; 22(5):1150-60.
    View in: PubMed
    Score: 0.006
  37. Dual Roles of RNF2 in Melanoma Progression. Cancer Discov. 2015 Dec; 5(12):1314-27.
    View in: PubMed
    Score: 0.006
  38. The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcoma. Lab Invest. 2015 Aug; 95(8):951-61.
    View in: PubMed
    Score: 0.005
  39. Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway. Mol Cancer. 2015 Mar 07; 14:55.
    View in: PubMed
    Score: 0.005
  40. NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma. Oncogene. 2015 Sep 24; 34(39):5069-79.
    View in: PubMed
    Score: 0.005
  41. Nuclear PTEN tumor-suppressor functions through maintaining heterochromatin structure. Cell Cycle. 2015; 14(14):2323-32.
    View in: PubMed
    Score: 0.005
  42. Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcoma. Oncotarget. 2014 Oct 15; 5(19):9065-78.
    View in: PubMed
    Score: 0.005
  43. EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis. J Pathol. 2014 Feb; 232(3):308-18.
    View in: PubMed
    Score: 0.005
  44. Mesenchymal to epithelial transition in sarcomas. Eur J Cancer. 2014 Feb; 50(3):593-601.
    View in: PubMed
    Score: 0.005
  45. Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry. PLoS One. 2013; 8(6):e67306.
    View in: PubMed
    Score: 0.005
  46. Heterogeneity and immunophenotypic plasticity of malignant cells in human liposarcomas. Stem Cell Res. 2013 Sep; 11(2):772-81.
    View in: PubMed
    Score: 0.005
  47. Modeling Ewing sarcoma tumors in vitro with 3D scaffolds. Proc Natl Acad Sci U S A. 2013 Apr 16; 110(16):6500-5.
    View in: PubMed
    Score: 0.005
  48. Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors. Mol Cancer Ther. 2012 Aug; 11(8):1758-69.
    View in: PubMed
    Score: 0.004
  49. INK4a/ARF [corrected] inactivation with activation of the NF-?B/IL-6 pathway is sufficient to drive the development and growth of angiosarcoma. Cancer Res. 2012 Sep 15; 72(18):4682-95.
    View in: PubMed
    Score: 0.004
  50. Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma. Clin Cancer Res. 2012 Sep 01; 18(17):4633-45.
    View in: PubMed
    Score: 0.004
  51. Unphosphorylated STAT1 promotes sarcoma development through repressing expression of Fas and bad and conferring apoptotic resistance. Cancer Res. 2012 Sep 15; 72(18):4724-32.
    View in: PubMed
    Score: 0.004
  52. Expression of ERG, an Ets family transcription factor, identifies ERG-rearranged Ewing sarcoma. Mod Pathol. 2012 Oct; 25(10):1378-83.
    View in: PubMed
    Score: 0.004
  53. Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors. Clin Cancer Res. 2012 May 01; 18(9):2545-57.
    View in: PubMed
    Score: 0.004
  54. MiR-155 is a liposarcoma oncogene that targets casein kinase-1a and enhances ?-catenin signaling. Cancer Res. 2012 Apr 01; 72(7):1751-62.
    View in: PubMed
    Score: 0.004
  55. ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. J Pathol. 2012 Jun; 227(2):223-33.
    View in: PubMed
    Score: 0.004
  56. Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma. Clin Cancer Res. 2011 Sep 15; 17(18):5901-12.
    View in: PubMed
    Score: 0.004
  57. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res. 2011 Jun 15; 17(12):3943-55.
    View in: PubMed
    Score: 0.004
  58. New frontiers in the treatment of liposarcoma, a therapeutically resistant malignant cohort. Drug Resist Updat. 2011 Feb; 14(1):52-66.
    View in: PubMed
    Score: 0.004
  59. Wt1 ablation and Igf2 upregulation in mice result in Wilms tumors with elevated ERK1/2 phosphorylation. J Clin Invest. 2011 Jan; 121(1):174-83.
    View in: PubMed
    Score: 0.004
  60. Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Cancer Res. 2011 Jan 01; 71(1):185-96.
    View in: PubMed
    Score: 0.004
  61. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors. Lab Invest. 2011 Mar; 91(3):392-403.
    View in: PubMed
    Score: 0.004
  62. Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene. 2011 Jan 27; 30(4):457-70.
    View in: PubMed
    Score: 0.004
  63. TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo. Clin Cancer Res. 2010 May 01; 16(9):2591-604.
    View in: PubMed
    Score: 0.004
  64. Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. PLoS One. 2010 Apr 16; 5(4):e10105.
    View in: PubMed
    Score: 0.004
  65. Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma. PLoS One. 2009 Nov 30; 4(11):e8075.
    View in: PubMed
    Score: 0.004
  66. IFN regulatory factor 8 sensitizes soft tissue sarcoma cells to death receptor-initiated apoptosis via repression of FLICE-like protein expression. Cancer Res. 2009 Feb 01; 69(3):1080-8.
    View in: PubMed
    Score: 0.004
  67. Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma. Clin Cancer Res. 2008 Sep 01; 14(17):5466-75.
    View in: PubMed
    Score: 0.003
  68. Midkine enhances soft-tissue sarcoma growth: a possible novel therapeutic target. Clin Cancer Res. 2008 Aug 15; 14(16):5033-42.
    View in: PubMed
    Score: 0.003
  69. Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo. Clin Cancer Res. 2008 May 01; 14(9):2785-95.
    View in: PubMed
    Score: 0.003
  70. Impact of sentinel lymphadenectomy on survival in a murine model of melanoma. Clin Exp Metastasis. 2008; 25(3):191-9.
    View in: PubMed
    Score: 0.003
  71. Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep. 2007 May; 8(5):497-503.
    View in: PubMed
    Score: 0.003
  72. Insights into developmental mechanisms and cancers in the mammalian intestine derived from serial analysis of gene expression and study of the hepatoma-derived growth factor (HDGF). Development. 2005 Jan; 132(2):415-27.
    View in: PubMed
    Score: 0.003
  73. Kinetochore size variation in mammalian chromosomes: an image analysis study with evolutionary implications. J Cell Sci. 1989 Feb; 92 ( Pt 2):281-9.
    View in: PubMed
    Score: 0.002
  74. Effect of methylcellulose on the Murphy-Sturm lymphosarcoma in rats. J Natl Cancer Inst. 1962 Jun; 28:1255-67.
    View in: PubMed
    Score: 0.001
  75. Electron microscopic studies on frog virus 3 infection in HeLa cells at permissive and non-permissive temperatures. Arch Gesamte Virusforsch. 1974; 45(4):376-81.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.